Genetically modified t cells take on rare sarcomas

NCT ID NCT04044768

Ongoing Disease control Sponsor: USWM CT, LLC Source: ClinicalTrials.gov ↗

First seen Feb 06, 2026 · Last updated Jun 21, 2026 · Updated 23 times

Summary

This phase 2 trial tests a one-time infusion of a patient's own immune cells that have been genetically modified to recognize and attack cancer cells. It is for people with advanced synovial sarcoma or myxoid liposarcoma whose tumors have a specific marker (MAGE-A4) and who have already tried standard chemotherapy. The main goal is to see if the treatment shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Centre Leon Berard

Lyon, France
City of Hope

Duarte, California, 91010, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fred Hutch

Seattle, Washington, 98109, United States
Gustave Roussy Cancer Center

Villejuif, 94805, France
Hospital Haut Leveque, CHU Bordeaux

Pessac, 33604, France
Hospital Universitari Vall D'Hebron

Barcelona, Catalonia, 119-129, Spain
Hospital Universitario Virgen del Rocio

Seville, 41013, Spain
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Jacksonville

Jacksonville, Florida, 33612, United States
Medical College of WI Froedtert Hospital

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
National Cancer Institute

Bethesda, Maryland, 20892, United States
Northwestern University Robert H. Lurie Comprehensive Cancer Center

Chicago, Illinois, 60611, United States
Ohio State University

Columbus, Ohio, 43210, United States
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Stanford Cancer Center

Palo Alto, California, 94305, United States
Start Madrid-FJD, Fundación Jimѐnez Díaz

Madrid, 28040, Spain
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
UCLH Cancer Clinical Trials Unit

London, NW1 2PG, United Kingdom
University of Colorado

Aurora, Colorado, 80045, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
Vanderbilt

Nashville, Tennessee, 37212, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

afamitresgene autoleucel (ADP-A2M4) – a patient's own immune cells genetically modified to target cancer

What this could lead to

If successful, this could offer a new treatment option for people with advanced synovial sarcoma or myxoid liposarcoma who have few alternatives.

What could go wrong

This is a small, early-phase trial (52 participants) with no control group. The treatment may cause serious side effects, and it is not yet proven to work for everyone.

Conditions

The condition(s) this trial relates to.

myxoid liposarcoma myxoid/round cell liposarcoma sarcoma synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYXOID LIPOSARCOMA SYNOVIAL SARCOMA